2015 American Transplant Congress
microRNA-494 Promotes Cyclosporine-Induced Nephrotoxicity and Epithelial to Mesenchymal Transition By Inhibiting PTEN
Purpose: A major complication associated with cyclosporine (CsA) treatment is nephrotoxicity. MicroRNAs (miRs) have been shown to play an important role in various pathological conditions,…2015 American Transplant Congress
Evaluation of Medication Regimen Complexity Over Time Following Heart Re-Transplantation
Medication regimen complexity (MRC) includes many characteristics of a drug regimen. Previously, we showed that MRC is high and persists over time after primary heart…2015 American Transplant Congress
Kidney Transplant Function After Late Conversion to Belatacept (Nulojix®)
Introduction: In the long-term follow up of kidney transplants, chronic transplant nephropathy often in combination with CNI-toxicity is a major problem. With declining transplant function…2015 American Transplant Congress
No Pharmacokinetic Interaction Between Pantoprazole and Mycophenolic Acid in Renal Transplant Patents: A Randomized Crossover Study
Department of Nephrology, Charité University Hospital, Berlin, Germany.
Mycophenolic acid (MPA) is used as an immunosuppressive agent in renal transplant (tx) patients (pts). 2 formulations are on the market: The prodrug Mycophenolate-Mofetil (MMF)…2015 American Transplant Congress
Patient Self-Reported Adherence to and Perceptions Towards Immunosuppressive Medications at the Outpatient Renal Transplant Clinic at St. Joseph's Healthcare Hamilton (SJHH)
Objectives To gain insight into the immunosuppressant adherence of patients followed by the Outpatient Renal Transplant Clinic at St. Joseph's Healthcare Hamilton (SJHH) and to…2015 American Transplant Congress
CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment
Background: T-cell depleting strategies have become an integral part of immunosuppressive regimens in organ transplantation. Alemtuzumab is a humanized monoclonal antibody against CD52, a cell-surface…2015 American Transplant Congress
Prospective Study of a Steroid Free, Low Dose Tacrolimus and Everolimus Combination Regimen in Kidney Transplant
Calcineurin(CNI) based therapy is the cornerstone of immunosuppresion(IS) after kidney transplant. However chronic nephrotoxicity from CNI as been implicated in post-transplant renal dysfunction. We hypothesized…2015 American Transplant Congress
Kidney Transplantation After Hematopoietic Cell Transplantation in Plasma Cell Dyscrasias
INTRODUCTION:The plasma cell dyscrasias (PCD) include a number of entities such as multiple myeloma (MM), primary amyloidosis (AL) and Monoclonal immunoglobulin deposition disease (MIDD). Hematopoietic…2015 American Transplant Congress
Post-Kidney Transplant Infections in Desensitized Patients Receiving Thymoglobulin or Daclizumab Induction: Results of a Randomized Clinical Trial
Live donor kidney transplant recipients requiring desensitization for donor-specific antibody, who were enrolled in a single-center randomized trial of thymoglobulin vs. daclizumab induction, were evaluated…2015 American Transplant Congress
Evaluation of Donor-Specific Antibodies Through 7 Years With Belatacept in BENEFIT and BENEFIT-EXT
1Emory University, Atlanta; 2Bristol-Myers Squibb, Lawrenceville.
Purpose: The development of donor-specific antibody (DSA) is linked to an increased risk of antibody-mediated rejection and graft failure. The 3 year intent-to-treat results from…
- « Previous Page
- 1
- …
- 125
- 126
- 127
- 128
- 129
- …
- 138
- Next Page »